ClinicalTrials.gg
CompletedNCT02991118CLEAR WisdomUpdated Apr 27, 2020Results posted

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

A Phase 3 interventional study of bempedoic acid and placebo in Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, sponsored by Esperion Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-27.

Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
779
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
3rd of 21
779 · median 126
Started
2016
with 3 others
Phase 3
7 of 21
1 open now
Registered
9th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 9th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.

03

Conditions studied

  • Hypercholesterolemia
  • Atherosclerotic Cardiovascular Disease

Keywords

  • hyperlipidemia
  • cholesterol
  • familial hypercholesterolemia
  • atherosclerotic cardiovascular disease
  • ASCVD
  • HeFH
  • LDL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting LDL-C ≥100 mg/dL
  • High cardiovascular risk (diagnosis of HeFH and/or ASCVD)
  • Be on maximally tolerated lipid-modifying therapy (LMT), including maximally tolerated statin either alone or in combination with other LMTs

Exclusion criteria

Exclusion Criteria:

  • Total fasting triglyceride ≥500 mg/dL
  • Renal dysfunction or nephrotic syndrome or history of nephritis
  • (BMI) ≥50kg/m2
  • Significant cardiovascular disease or cardiovascular event in the past 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
779 participants (actual)

Study arms

  • Experimental
    bempedoic acid

    bempedoic acid 180 mg/day

    Drug: bempedoic acid

  • Placebo comparator
    Placebo

    Placebo control

    Drug: placebo

Interventions

  • bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

    Also known as: ETC-1002

  • Drugplacebo

    Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

    Also known as: placebo control

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)

    Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (atherosclerotic cardiovascular diseases \[ASCVD\] and heterozygous familial hypercholesterolemia \[HeFH\]) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 are imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Baseline; Week 12

Secondary outcomes

  1. Percent Change From Baseline to Week 24 in LDL-C

    Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 24 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Baseline; Week 24

  2. Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Baseline is defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Baseline; Week 12

  3. Percent Change From Baseline to Week 12 in Total Cholesterol (TC)

    Baseline is defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Baseline; Week 12

  4. Percent Change From Baseline to Week 12 in Apolipoprotein b (Apo B)

    Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing apo B data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

    Time frame: Baseline; Week 12

  5. Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)

    Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.

    Time frame: Baseline; Week 12

  6. Change From Baseline to Week 12 in LDL-C

    Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.

    Time frame: Baseline; Week 12

  7. Change From Baseline to Week 24 in LDL-C

    Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.

    Time frame: Baseline; Week 24

Other outcomes

  1. Percent Change From Baseline to Week 12 in Triglycerides (TGs)

    Baseline is defined as the mean of the TG values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TG was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 12

  2. Percent Change From Baseline to Week 12 in HDL-C

    Baseline is defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 12

  3. Percent Change From Baseline to Week 52 in LDL-C

    Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 52

  4. Percent Change From Baseline to Week 24 in Non-HDL-C

    Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 24

  5. Percent Change From Baseline to Week 52 in Non-HDL-C

    Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 52

  6. Percent Change From Baseline to Week 24 in TC

    Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 24

  7. Percent Change From Baseline to Week 52 in TC

    Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 52

  8. Percent Change From Baseline to Week 24 in Apo B

    Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 24

  9. Percent Change From Baseline to Week 52 in Apo B

    Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

    Time frame: Baseline; Week 52

  10. Percent Change From Baseline to Week 24 in hsCRP

    Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.

    Time frame: Baseline; Week 24

  11. Percent Change From Baseline to Week 52 in hsCRP

    Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.

    Time frame: Baseline; Week 52

  12. Change From Baseline to Week 52 in LDL-C

    Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data. Change from Baseline in LDL-C was analyzed using an ANCOVA model with change from baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and baseline as a covariate.

    Time frame: Baseline; Week 52

07

Results

Posted Apr 27, 2020

Participant flow

A total of 779 participants were randomized 2:1 to receive either bempedoic acid or placebo.

Participant flow — Overall Study
MilestonePlaceboBempedoic Acid
Started257522
Completed250490
Not completed732
Withdrew: Death38
Withdrew: Protocol violation03
Withdrew: Physician decision01
Withdrew: Moved out of the country01
Withdrew: Adverse event22
Withdrew: Withdrawal by subject17
Withdrew: Could not attend study visits01
Withdrew: Lost to follow-up19

Outcome measures

PrimaryPercent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)

Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (atherosclerotic cardiovascular diseases \[ASCVD\] and heterozygous familial hypercholesterolemia \[HeFH\]) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 are imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)2.35 ± 1.446-15.07 ± 1.073
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -17.42 · 95% CI -20.951 to -13.896
SecondaryPercent Change From Baseline to Week 24 in LDL-C

Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 24 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in LDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in LDL-C2.66 ± 1.910-12.10 ± 1.479
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -14.77 · 95% CI -19.504 to -10.027
SecondaryPercent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

Baseline is defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)2.28 ± 1.351-10.75 ± 0.952
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -13.03 · 95% CI -16.270 to -9.794
SecondaryPercent Change From Baseline to Week 12 in Total Cholesterol (TC)

Baseline is defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)1.26 ± 1.010-9.94 ± 0.688
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -11.20 · 95% CI -13.599 to -8.801
SecondaryPercent Change From Baseline to Week 12 in Apolipoprotein b (Apo B)

Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing apo B data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Apolipoprotein b (Apo B)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Apolipoprotein b (Apo B)3.73 ± 1.340-9.29 ± 0.851
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -13.02 · 95% CI -16.130 to -9.907
SecondaryPercent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)

Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.

Time frame:
Baseline; Week 12
Reported as:
Median · percent change
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)-9.366 (-36.320 to 35.241)-18.699 (-46.067 to 23.864)
Statistical analysis
  • Placebo vs Bempedoic Acid · Wilcoxon Rank Sum Test · p = <0.039 · Location shift: -8.733 · 95% CI -17.238 to -0.434The location shift and asymptotic 95% confidence interval are based on Hodges-Lehman estimation.
SecondaryChange From Baseline to Week 12 in LDL-C

Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.

Time frame:
Baseline; Week 12
Reported as:
Mean · mg/dL
Change From Baseline to Week 12 in LDL-C
mg/dLPlaceboBempedoic Acid
Change From Baseline to Week 12 in LDL-C0.0 ± 30.62-21.2 ± 30.82
SecondaryChange From Baseline to Week 24 in LDL-C

Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.

Time frame:
Baseline; Week 24
Reported as:
Mean · mg/dL
Change From Baseline to Week 24 in LDL-C
mg/dLPlaceboBempedoic Acid
Change From Baseline to Week 24 in LDL-C-1.0 ± 37.51-18.7 ± 35.76
Other pre-specifiedPercent Change From Baseline to Week 12 in Triglycerides (TGs)

Baseline is defined as the mean of the TG values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TG was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Triglycerides (TGs)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Triglycerides (TGs)6.12 ± 2.29411.01 ± 2.312
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = 0.134 · Difference in ls mean: 4.89 · 95% CI -1.504 to 11.292
Other pre-specifiedPercent Change From Baseline to Week 12 in HDL-C

Baseline is defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in HDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in HDL-C-0.25 ± 0.864-6.38 ± 0.741
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -6.13 · 95% CI -8.369 to -3.896
Other pre-specifiedPercent Change From Baseline to Week 52 in LDL-C

Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 52 in LDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in LDL-C-0.97 ± 1.830-13.24 ± 1.412
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -12.27 · 95% CI -16.813 to -7.722
Other pre-specifiedPercent Change From Baseline to Week 24 in Non-HDL-C

Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in Non-HDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in Non-HDL-C2.44 ± 1.611-10.19 ± 1.200
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -12.63 · 95% CI -16.580 to -8.682
Other pre-specifiedPercent Change From Baseline to Week 52 in Non-HDL-C

Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 52 in Non-HDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in Non-HDL-C-0.42 ± 1.605-10.34 ± 1.150
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -9.92 · 95% CI -13.803 to -6.037
Other pre-specifiedPercent Change From Baseline to Week 24 in TC

Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in TC
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in TC1.52 ± 1.216-9.25 ± 0.857
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -10.77 · 95% CI -13.698 to -7.848
Other pre-specifiedPercent Change From Baseline to Week 52 in TC

Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 52 in TC
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in TC-1.89 ± 1.199-10.25 ± 0.828
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -8.36 · 95% CI -11.223 to -5.493
Other pre-specifiedPercent Change From Baseline to Week 24 in Apo B

Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in Apo B
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in Apo B4.39 ± 2.090-8.61 ± 1.267
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -13.00 · 95% CI -17.829 to -8.175
Other pre-specifiedPercent Change From Baseline to Week 52 in Apo B

Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.

Time frame:
Baseline; Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 52 in Apo B
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in Apo B3.01 ± 1.502-6.56 ± 0.983
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -9.58 · 95% CI -13.107 to -6.047
Other pre-specifiedPercent Change From Baseline to Week 24 in hsCRP

Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.

Time frame:
Baseline; Week 24
Reported as:
Median · percent change
Percent Change From Baseline to Week 24 in hsCRP
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in hsCRP1.563 (-32.174 to 47.500)-24.107 (-51.502 to 14.035)
Statistical analysis
  • Placebo vs Bempedoic Acid · Wilcoxon Rank Sum Test · p = <0.001 · Location shift: -21.278 · 95% CI -32.250 to -10.034The location shift and asymptotic 95% confidence interval are based on Hodges-Lehman estimation.
Other pre-specifiedPercent Change From Baseline to Week 52 in hsCRP

Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus baseline value\] divided by \[baseline value\]) multiplied by 100.

Time frame:
Baseline; Week 52
Reported as:
Median · percent change
Percent Change From Baseline to Week 52 in hsCRP
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in hsCRP-6.250 (-39.286 to 41.810)-16.727 (-50.877 to 31.429)
Statistical analysis
  • Placebo vs Bempedoic Acid · Wilcoxon Rank Sum Test · p = 0.102 · Location shift: -7.587 · 95% CI -16.978 to 1.653The location shift and asymptotic 95% confidence interval are based on Hodges-Lehman estimation.
Other pre-specifiedChange From Baseline to Week 52 in LDL-C

Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data. Change from Baseline in LDL-C was analyzed using an ANCOVA model with change from baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and baseline as a covariate.

Time frame:
Baseline; Week 52
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 52 in LDL-C
mg/dLPlaceboBempedoic Acid
Change From Baseline to Week 52 in LDL-C-4.71 ± 2.216-19.78 ± 1.433
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -15.07 · 95% CI -20.260 to -9.878

Adverse events

Collected over up to Week 52. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/257 (0.8%)48/257 (18.7%)88/257 (34.2%)
Bempedoic Acid6/522 (1.1%)106/522 (20.3%)211/522 (40.4%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventPlaceboBempedoic Acid
Angina unstableCardiac disorders6/2579/522
Coronary artery diseaseCardiac disorders6/2577/522
Angina pectorisCardiac disorders1/25712/522
Myocardial ischaemiaCardiac disorders4/2572/522
DyspnoeaRespiratory, thoracic and mediastinal disorders4/2570/522
Acute myocardial infarctionCardiac disorders3/2572/522
OsteoarthritisMusculoskeletal and connective tissue disorders2/2575/522
Cardiac arrestCardiac disorders2/2572/522
Cardiac failureCardiac disorders2/2570/522
Myocardial infarctionCardiac disorders2/2572/522
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboBempedoic Acid
NasopharyngitisInfections and infestations13/25727/522
Urinary tract infectionInfections and infestations5/25724/522
HyperuricaemiaMetabolism and nutrition disorders5/25722/522
Upper respiratory tract infectionInfections and infestations9/25719/522
FatigueGeneral disorders9/2576/522
DizzinessNervous system disorders9/2578/522
ArthralgiaMusculoskeletal and connective tissue disorders8/25718/522
MyalgiaMusculoskeletal and connective tissue disorders8/25715/522
DiarrhoeaGastrointestinal disorders7/25716/522
Lower respiratory tract infectionInfections and infestations7/2577/522

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBempedoic AcidTotal
Mean64.7 ± 8.7364.1 ± 8.8264.3 ± 8.79
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBempedoic AcidTotal
Female89194283
Male168328496
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBempedoic AcidTotal
American Indian or Alaska Native101
Asian044
Black or African American122436
Native Hawaiian or Other Pacific Islander011
White244491735
Multiple022
Mean low-density lipoprotein cholesterol (LDL-C)
Mean low-density lipoprotein cholesterol (LDL-C)(milligrams per deciliter (mg/dL))PlaceboBempedoic AcidTotal
Mean122.4 ± 38.30119.4 ± 37.75120.43 ± 37.931
LDL-C category
LDL-C category(Participants)PlaceboBempedoic AcidTotal
<130 mg/dL173365538
≥130 and <160 mg/dL4589134
≥160 mg/dL3968107
Mean non-high-density lipoprotein cholesterol (non-HDL-C)
Mean non-high-density lipoprotein cholesterol (non-HDL-C)(mg/dL)PlaceboBempedoic AcidTotal
Mean153.7 ± 44.36150.7 ± 42.75151.7 ± 43.28
Mean total cholesterol (TC)
Mean total cholesterol (TC)(mg/dL)PlaceboBempedoic AcidTotal
Mean204.8 ± 46.06202.1 ± 42.71203.0 ± 43.83
Mean apolipoprotein B (apoB)
Mean apolipoprotein B (apoB)(mg/dL)PlaceboBempedoic AcidTotal
Mean118.6 ± 30.53116.2 ± 29.58117.0 ± 29.90

12 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Clearwater, Florida, United States
  • Georgetown, Texas, United States
09

References and documents

Publications

  • Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019 Nov 12;322(18):1780-1788. doi: 10.1001/jama.2019.16585. Erratum In: JAMA. 2020 Jan 21;323(3):282. doi: 10.1001/jama.2019.20661. PubMed 31714986 ↗
  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8. PubMed 21067804 ↗
  • Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. PubMed 26039521 ↗
  • Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm. 2013 Mar;19(2):139-49. doi: 10.18553/jmcp.2013.19.2.139. PubMed 23461430 ↗
  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. No abstract available. Erratum In: Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8. Circulation. 2015 Dec 22;132(25):e396. doi: 10.1161/CIR.0000000000000346. PubMed 24222016 ↗
  • Ballantyne CM, Bays HE, Louie MJ, Smart J, Zhang Y, Ray KK. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 Aug 2;11(15):e024531. doi: 10.1161/JAHA.121.024531. Epub 2022 Aug 2. PubMed 35916348 ↗
  • Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020 Oct 1;5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314. PubMed 32609313 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Aug 2018, 21 months.

Results were first posted in Apr 2020, 1 year 8 months after primary completion. A results delay was requested in Nov 2018.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2016
First posted
Dec 13, 2016
StartActual
Nov 18, 2016
Primary completionActual
Aug 22, 2018
CompletionActual
Aug 22, 2018
Results delay requested
Nov 8, 2018
Results first posted
Apr 27, 2020
Last update
Apr 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02991118
Responsible party
Sponsor
First posted
Dec 13, 2016
Start date
Nov 18, 2016
Primary completion
Aug 22, 2018
Completion
Aug 22, 2018
Results posted
Apr 27, 2020
Last update
Apr 27, 2020

Study contacts

Ron Haberman, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion